Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25713483 | 0.80 | TDP1 (0.64) | SMN1; SMN2RAB9ANPC1KMT2ALMNA | |
| SCHEMBL7165686 | 0.80 | RAB9A (0.57) | NAMPTSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL3937264 | 0.78 | LMNA (0.53) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL20937443 | 0.78 | LMNA (0.48) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL30276208 | 0.78 | LMNA (0.48) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL20389370 | 0.77 | NAMPT (0.76) | NAMPTSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL12852739 | 0.75 | MEN1 (0.51) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL13327790 | 0.74 | POLB (0.55) | SMN1; SMN2RAB9ANPC1POLBMGLL | |
| SCHEMBL18916793 | 0.74 | JMJD6 (0.47) | NAMPTSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL8726462 | 0.73 | NAMPT (0.70) | NAMPTSMN1; SMN2RAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | ALKAHEST, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | NAMPT 3447/4885SMN1; SMN2 3606/4885RAB9A 1601/4885 |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | NAMPT 1022/4885SMN1; SMN2 1117/4885RAB9A 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.